GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (STU:49B) » Definitions » Price-to-Funds-From-Operations

BeiGene (STU:49B) Price-to-Funds-From-Operations : (As of Jun. 10, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


BeiGene (STU:49B) Business Description

Industry
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.